Atrion - ATRI Stock Forecast, Price & News

Atrion's stock was trading at $559.45 at the beginning of 2023. Since then, ATRI shares have increased by 24.4% and is now trading at $696.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our ATRI earnings forecast.

Atrion Co. (NASDAQ:ATRI) released its quarterly earnings results on Tuesday, November, 8th. The medical instruments supplier reported $4.94 earnings per share for the quarter. The medical instruments supplier earned $44.63 million during the quarter. Atrion had a net margin of 19.24% and a trailing twelve-month return on equity of 14.16%.

Atrion announced a quarterly dividend on Monday, November 14th. Shareholders of record on Thursday, December 1st will be given a dividend of $2.15 per share on Thursday, December 15th. This represents a $8.60 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Wednesday, November 30th.
Read our dividend analysis for ATRI.

Atrion (NASDAQ:ATRI) pays an annual dividend of $8.60 per share and currently has a dividend yield of 1.25%. The company has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for ATRI.

1 employees have rated Atrion Chief Executive Officer David A. Batta on Glassdoor.com. David A. Batta has an approval rating of 100% among the company's employees. This puts David A. Batta in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Atrion to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include International Paper (IP), AT&T (T), WestRock (WRK), AbbVie (ABBV), Caterpillar (CAT), Eastman Chemical (EMN), Gilead Sciences (GILD), Altria Group (MO), Pfizer (PFE) and Philip Morris International (PM).

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

Atrion's stock is owned by many different institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (1.74%), ProShare Advisors LLC (0.84%), ICW Investment Advisors LLC (0.13%), Allspring Global Investments Holdings LLC (0.08%), Vestmark Advisory Solutions Inc. (0.07%) and Strs Ohio (0.06%). Insiders that own company stock include Emile A Battat and Jeffery Strickland.
View institutional ownership trends.

Shares of ATRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRI stock can currently be purchased for approximately $696.04.

Atrion (NASDAQ:ATRI) has a market capitalization of $1.23 billion and generates $165.01 million in revenue each year. The medical instruments supplier earns $33.06 million in net income (profit) each year or $19.35 on an earnings per share basis.

The company employs 667 workers across the globe.

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The official website for the company is www.atrioncorp.com. The medical instruments supplier can be reached via phone at (972) 390-9800, via email at ir-info@atrioncorp.com, or via fax at 972-396-7581.